SLC25A14: A Potential Drug Target and Biomarker for Mitochondrial Carrier Protein

Target Name: SLC25A14

NCBI ID: G9016

SLC25A14

SLC25A14: A Potential Drug Target and Biomarker for Mitochondrial Carrier Protein

Abstract:

SLC25A14, a member of the Solute Carrier Family 25 (SCF25), has been identified as a potential drug target and biomarker for mitochondrial carrier protein. It plays a crucial role in the transport of various nutrients, including essential amino acids, into the mitochondria, where they can be utilized for energy production. The identification and characterization of SLC25A14 as a drug target and biomarker make it an attractive candidate for the development of new therapeutic approaches for various neurological and psychiatric disorders.

Introduction:

Mitochondria are essential organelles for the survival of eukaryotic cells. They are responsible for generating the majority of the cell's energy, primarily in the form of ATP, through the process of cellular respiration. Mitochondria also participate in the synthesis of various essential nutrients, including amino acids, which are critical for the maintenance of cellular homeostasis and for the synthesis of neurotransmitters involved in brain function. The mitochondrial transport system is a complex network of proteins that ensure the efficient delivery of nutrients into the mitochondria.

SLC25A14, a member of the Solute Carrier Family 25 (SCF25), is an essential protein involved in the mitochondrial transport system. It functions as a carrier protein for the transport of various essential amino acids, including Lysine, into the mitochondria. The SLC25A14 gene has four splice variants, resulting in four unique transcript variants, designated SLC25A14-long, SLC25A14-short, SLC25A14-long reverse, and SLC25A14-short reverse.

SLC25A14 function:

SLC25A14 is a transmembrane protein that consists of a catalytic alpha-helices and a cytoplasmic tail. It has a calculated molecular weight of 41.1 kDa and a pre-membrane potential of 130 mV. SLC25A14 is expressed in various tissues, including brain, heart, and skeletal muscles, and its levels vary depending on the experimental conditions.

SLC25A14 plays a crucial role in the transport of essential amino acids into the mitochondria. It is known to interact with the protein Translocator Proteus (TSP), which is involved in the transfer of amino acids across the mitochondrial inner membrane during the citric acid cycle. SLC25A14 modulates the activity of TSP by interacting with its cytoplasmic region, which is thought to influence the rate of amino acid transfer.

SLC25A14 is also involved in the regulation of mitochondrial dynamics, as demonstrated by its ability to modulate the mitochondrial protein content and localization. SLC25A14 has been shown to interact with the protein Mitofusin-1 (Mf1), which is involved in regulating mitochondrial fusion and fission. This interaction between SLC25A14 and Mf1 suggests a potential role for SLC25A14 in the regulation of mitochondrial dynamics and function.

Drug targeting:

The identification of SLC25A14 as a potential drug target makes it an attractive candidate for the development of new therapeutic approaches for various neurological and psychiatric disorders. SLC25A14 functions as a carrier protein for the transport of essential amino acids into the mitochondria, which are critical for the maintenance of cellular homeostasis and for the synthesis of neurotransmitters involved in brain function.

SLC25A14 can be targeted by small molecules, such as those derived from natural compounds, to modulate its activity and disrupt its function in diseases associated with mitochondrial dysfunction, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, SLC25A14 can

Protein Name: Solute Carrier Family 25 Member 14

Functions: Participates in the mitochondrial proton leak measured in brain mitochondria

The "SLC25A14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets